Alembic Pharma’s generic cancer drug Bosutinib Tablets 400 mg gets U.S. FDA nod
Alembic Pharmaceuticals has received tentative approval from the U.S. Food and Drug Administration (U.S. FDA) for its generic of cancer drug Bosutinib Tablets, 400 mg. Bosutinib Tablets, 400 mg, had an estimated market size of $251 million for the twelve months ended September 2025, the drugmaker said, citing IQVIA numbers, in a release announcing the…